CagriSema
Fat LossInvestigational amylin + GLP-1 combinationEmerging
Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- 8/23/2026
- Targets
- GLP-1 receptorAmylin receptor
Overview
Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.
Protocol
- Dosage Range
- Weekly fixed-dose combinations in REDEFINE trials
- Frequency
- Once weekly
- Cycle
- Long-term trial setting
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Combines GLP-1 receptor agonism with long-acting amylin-receptor agonism for complementary appetite and gastric-emptying effects.
Targets
GLP-1 receptorAmylin receptor
Studies
- CagriSema phase 2 obesity— Journal/year not available
Benefits
Investigational dual-pathway obesity candidate
Potential Side Effects
- Nausea
- Constipation
- GI class effects
References
- PMID 37366314External link · Year —
- WADA Prohibited List 2026External link · Year —